ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Johnson & Johnson, Fosun Pharma and AstraZeneca side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Johnson & Johnson×Fosun Pharma×AstraZeneca×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Johnson & JohnsonFosun PharmaAstraZeneca
studies on the registry3,7092024,197
open to participants now14686298
phase 3 studies under way9523200
reach primary completion within a year8739168
programswith a study of their own in two years56+4 named only49+18 named only119+5 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJohnson & JohnsonFosun PharmaAstraZeneca
Phase 1

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%

Fosun Pharma: 27 of its 49 programs at phase 1

  1. HLX319phase 1
  2. Anti-PD-1/IL-2 Fusion Protein TEV-56278phase 1
  3. Cetuximabphase 1
  4. FXS0260phase 1
  5. FXS0683phase 1

and 22 more — sign in to see them all

55%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%
Phase 2

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%

Fosun Pharma: 9 of its 49 programs at phase 2

  1. BRAF V600E Inhibitor HLX208phase 2
  2. Bcl-2 Inhibitor LOXO-338phase 2
  3. FKC289phase 2
  4. FXR0906phase 2
  5. XH-S003 Capsulephase 2

and 4 more — sign in to see them all

18%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
Phase 3

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%

Fosun Pharma: 13 of its 49 programs at phase 3

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. luvometinibphase 3
  5. dulpatatugphase 3

and 8 more — sign in to see them all

27%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%
Approved, new studies

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%
00%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Johnson & Johnson25 readouts · 8 phase 3·

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
Fosun Pharma21 readouts · 3 phase 3

Fosun Pharma, Nov ’26: 2 programs whose next study reaches primary completion

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3 · Nov 22 · NCT06839066
  2. FKC876early phase 1 · Nov 30 · NCT07606937

Fosun Pharma, Dec ’26: 2 programs whose next study reaches primary completion

  1. HLX13phase 3 · Dec 0 · NCT07176650
  2. Bcl-2 Inhibitor LOXO-338phase 2 · Dec 1 · NCT06858618

Fosun Pharma, Jan ’27: 1 program whose next study reaches primary completion

  1. HLX29phase 1 · Jan 31 · NCT07776132

Fosun Pharma, Feb ’27: 1 program whose next study reaches primary completion

  1. FXS5626phase 3 · Feb 28 · NCT07552012

Fosun Pharma, Mar ’27: 2 programs whose next study reaches primary completion

  1. HLX48phase 1 · Mar 0 · NCT07473726
  2. HLX37phase 3 · Mar 30 · NCT07274813

Fosun Pharma, Apr ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. HLX17phase 3 · Apr 9 · NCT06847334
  2. HLX319phase 1 · Apr 23 · NCT07601620
  3. FXS887phase 1 · Apr 28 · NCT07345637
  4. FXS6837phase 3 · Apr 29 · NCT07949799
  5. luvometinibphase 3 · Apr 30 · NCT07004075

Fosun Pharma, May ’27: 1 program whose next study reaches primary completion

  1. HLX15phase 3 · May 25 · NCT07477587

Fosun Pharma, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. dulpatatugphase 3 · Jun 1 · NCT06532006
  2. HLX3902phase 1 · Jun 29 · NCT07533708
  3. Cetuximabphase 1 · Jun 30 · NCT07543471

Fosun Pharma, Jul ’27: 1 program whose next study reaches primary completion

  1. pimurutamabphase 3 · Jul 28 · NCT07358585

Fosun Pharma, Aug ’27: 1 program whose next study reaches primary completion

  1. HLX18phase 1 · Aug 12 · NCT07518043

Fosun Pharma, Sep ’27: 2 programs whose next study reaches primary completion

  1. HLX109phase 1 · Sep 20 · NCT07935941
  2. FXR0906phase 2 · Sep 24 · NCT07766759
·
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Fosun Pharma

New programs 5

  • HLX49phase 1 · first study · Nov 12
  • HLX105phase 1 · first study · Nov 4
  • FXS0260phase 1 · first study · Oct 25
  • HLX109phase 1 · first study · Oct 18
  • FXS4640phase 1 · first study · Sep 23

Reached a new phase 3

  • FXR0906phase 2 · Oct 13
  • HLX37phase 3 · Oct 4 · Carcinoma, Non-Small-Cell Lung
  • FXS5626phase 3 · Sep 17 · Uveitis

Study stopped 0

None

Primary completion later 1

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Where they overlap

Conditions where at least two of them have programs: 44 in all. A program counts in each condition its studies name most.

ConditionJohnson & JohnsonFosun PharmaAstraZeneca
Carcinoma, Non-Small-Cell Lungall three · compare here

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

Fosun Pharma in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. serplulimabphase 3
  3. pimurutamabphase 3
  4. HLX17phase 3
  5. HLX37phase 3

and 6 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Fosun Pharma in Breast Neoplasms: 6 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. dulpatatugphase 3
  3. HLX87phase 3
  4. hx22phase 3
  5. HLX319phase 1

and 1 more — sign in to see them all

Their studies: Fosun Pharma’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Neoplasmsall three · compare here

Fosun Pharma in Neoplasms: 5 programs

  1. anlotinibphase 2
  2. Folfox protocolphase 2
  3. Cetuximabphase 1
  4. HLX05phase 1
  5. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Neoplasms in search

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Multiple Myelomaall three · compare here

Johnson & Johnson in Multiple Myeloma: 6 programs

  1. ramantamigphase 3
  2. fludarabinephase 2
  3. JNJ-102299639phase 1
  4. JNJ-87562761phase 1
  5. teclistamabapproved, new study

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Multiple Myeloma in search

Fosun Pharma in Multiple Myeloma: 2 programs

  1. HLX15phase 3
  2. hyaluronidase (human recombinant)phase 1

Their studies: Fosun Pharma’s studies of Multiple Myeloma in search

Stomach Neoplasmsall three · compare here

Johnson & Johnson in Stomach Neoplasms: 1 program

  1. amivantamabphase 3

Their studies: Johnson & Johnson’s studies of Stomach Neoplasms in search

Fosun Pharma in Stomach Neoplasms: 3 programs

  1. serplulimabphase 3
  2. dulpatatugphase 3
  3. Folfox protocolphase 2

Their studies: Fosun Pharma’s studies of Stomach Neoplasms in search

Renal Insufficiencyall three · compare here

Johnson & Johnson in Renal Insufficiency: 2 programs

  1. seltorexantphase 3
  2. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Renal Insufficiency in search

Fosun Pharma in Renal Insufficiency: 1 program

  1. nacubactamno phase

Their studies: Fosun Pharma’s studies of Renal Insufficiency in search

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Colorectal Neoplasmsall three · compare here

Johnson & Johnson in Colorectal Neoplasms: 3 programs

  1. amivantamabphase 3
  2. olomorasibphase 2
  3. JNJ-89402638phase 1

Their studies: Johnson & Johnson’s studies of Colorectal Neoplasms in search

Fosun Pharma in Colorectal Neoplasms: 5 programs

  1. serplulimabphase 3
  2. BRAF V600E Inhibitor HLX208phase 2
  3. Folfox protocolphase 2
  4. XS-03phase 2
  5. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Leukemia, Lymphocytic, Chronic, B-Cellall three · compare here

Johnson & Johnson in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. fludarabinephase 2
  2. safimaltibphase 1
  3. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Fosun Pharma in Leukemia, Lymphocytic, Chronic, B-Cell: 1 program

  1. Bcl-2 Inhibitor LOXO-338phase 2

Their studies: Fosun Pharma’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Carcinoma, Hepatocellularall three · compare here

Johnson & Johnson in Carcinoma, Hepatocellular: 1 program

  1. amivantamabphase 3

Their studies: Johnson & Johnson’s studies of Carcinoma, Hepatocellular in search

Fosun Pharma in Carcinoma, Hepatocellular: 1 program

  1. HLX13phase 3

Their studies: Fosun Pharma’s studies of Carcinoma, Hepatocellular in search

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

Squamous Cell Carcinoma of Head and Neckall three · compare here

Johnson & Johnson in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. amivantamabphase 3
  2. hafnium oxidephase 3

Their studies: Johnson & Johnson’s studies of Squamous Cell Carcinoma of Head and Neck in search

Fosun Pharma in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. pimurutamabphase 3
  2. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Squamous Cell Carcinoma of Head and Neck in search

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Myasthenia Gravisall three · compare here

Johnson & Johnson in Myasthenia Gravis: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Myasthenia Gravis in search

Fosun Pharma in Myasthenia Gravis: 1 program

  1. hyaluronidase (human recombinant)phase 1

Their studies: Fosun Pharma’s studies of Myasthenia Gravis in search

AstraZeneca in Myasthenia Gravis: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Myasthenia Gravis in search

Prostatic Neoplasms2 of 3 · compare here–

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Leukemia, Myeloid, Acute2 of 3 · compare here

Johnson & Johnson in Leukemia, Myeloid, Acute: 11 programs

  1. bleximenibphase 3
  2. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  3. JNJ-87801493phase 1
  4. JNJ-64264681phase 1
  5. safimaltibphase 1

and 6 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Leukemia, Myeloid, Acute in search

Fosun Pharma in Leukemia, Myeloid, Acute: 1 program

  1. Bcl-2 Inhibitor LOXO-338phase 2

Their studies: Fosun Pharma’s studies of Leukemia, Myeloid, Acute in search

–
Asthma2 of 3 · compare here

Johnson & Johnson in Asthma: 1 program

  1. JNJ-95597528phase 2

Their studies: Johnson & Johnson’s studies of Asthma in search

–

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

Fosun Pharma in Pulmonary Disease, Chronic Obstructive: 1 program

  1. fxs7553 doseno phase

Their studies: Fosun Pharma’s studies of Pulmonary Disease, Chronic Obstructive in search

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Colitis, Ulcerative2 of 3 · compare here

Johnson & Johnson in Colitis, Ulcerative: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Colitis, Ulcerative in search

–

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Crohn Disease2 of 3 · compare here

Johnson & Johnson in Crohn Disease: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Crohn Disease in search

–

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

Endometrial Neoplasms2 of 3 · compare here–

Fosun Pharma in Endometrial Neoplasms: 1 program

  1. anlotinibphase 2

Their studies: Fosun Pharma’s studies of Endometrial Neoplasms in search

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

Lymphoma, B-Cell2 of 3 · compare here–

Fosun Pharma in Lymphoma, B-Cell: 2 programs

  1. FXS0683phase 1
  2. XS-04phase 1

Their studies: Fosun Pharma’s studies of Lymphoma, B-Cell in search

Neoplasm Metastasis2 of 3 · compare here–

Fosun Pharma in Neoplasm Metastasis: 2 programs

  1. serplulimabphase 3
  2. luvometinibphase 3

Their studies: Fosun Pharma’s studies of Neoplasm Metastasis in search

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Small Cell Lung Carcinoma2 of 3 · compare here–

Fosun Pharma in Small Cell Lung Carcinoma: 3 programs

  1. serplulimabphase 3
  2. anlotinibphase 2
  3. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Small Cell Lung Carcinoma in search

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Triple Negative Breast Neoplasms2 of 3 · compare here–

Fosun Pharma in Triple Negative Breast Neoplasms: 1 program

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3

Their studies: Fosun Pharma’s studies of Triple Negative Breast Neoplasms in search

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Alzheimer Disease2 of 3 · compare here

Johnson & Johnson in Alzheimer Disease: 3 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. JNJ-64042056phase 2

Their studies: Johnson & Johnson’s studies of Alzheimer Disease in search

Fosun Pharma in Alzheimer Disease: 1 program

  1. GV-971no phase

Their studies: Fosun Pharma’s studies of Alzheimer Disease in search

–
Hemoglobinuria, Paroxysmal2 of 3 · compare here–

Fosun Pharma in Hemoglobinuria, Paroxysmal: 2 programs

  1. FXS6837phase 3
  2. XH-S003 Capsulephase 2

Their studies: Fosun Pharma’s studies of Hemoglobinuria, Paroxysmal in search

AstraZeneca in Hemoglobinuria, Paroxysmal: 2 programs

  1. ravulizumabapproved, new study
  2. eculizumabapproved, new study

Their studies: AstraZeneca’s studies of Hemoglobinuria, Paroxysmal in search

Lupus Erythematosus, Systemic2 of 3 · compare here

Johnson & Johnson in Lupus Erythematosus, Systemic: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Lupus Erythematosus, Systemic in search

–
Melanoma2 of 3 · compare here–

Fosun Pharma in Melanoma: 1 program

  1. HLX18phase 1

Their studies: Fosun Pharma’s studies of Melanoma in search

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Arthritis, Rheumatoid2 of 3 · compare here

Johnson & Johnson in Arthritis, Rheumatoid: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Arthritis, Rheumatoid in search

–

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Colonic Neoplasms2 of 3 · compare here–

Fosun Pharma in Colonic Neoplasms: 1 program

  1. pimurutamabphase 3

Their studies: Fosun Pharma’s studies of Colonic Neoplasms in search

AstraZeneca in Colonic Neoplasms: 2 programs

  1. oleclumabphase 3
  2. monalizumabphase 3

Their studies: AstraZeneca’s studies of Colonic Neoplasms in search

Dermatitis, Atopic2 of 3 · compare here

Johnson & Johnson in Dermatitis, Atopic: 2 programs

  1. JNJ-95597528phase 2
  2. JNJ-95475939phase 2

Their studies: Johnson & Johnson’s studies of Dermatitis, Atopic in search

–

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Glomerulonephritis, Membranous2 of 3 · compare here–

Fosun Pharma in Glomerulonephritis, Membranous: 1 program

  1. FKC289phase 2

Their studies: Fosun Pharma’s studies of Glomerulonephritis, Membranous in search

AstraZeneca in Glomerulonephritis, Membranous: 2 programs

  1. surovatamigphase 3
  2. ALXN1920phase 2

Their studies: AstraZeneca’s studies of Glomerulonephritis, Membranous in search

Hepatic Insufficiency2 of 3 · compare here

Johnson & Johnson in Hepatic Insufficiency: 1 program

  1. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Hepatic Insufficiency in search

–

AstraZeneca in Hepatic Insufficiency: 2 programs

  1. atirmociclibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Hepatic Insufficiency in search

Lymphoma, Mantle-Cell2 of 3 · compare here

Johnson & Johnson in Lymphoma, Mantle-Cell: 1 program

  1. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Lymphoma, Mantle-Cell in search

–

AstraZeneca in Lymphoma, Mantle-Cell: 2 programs

  1. pirtobrutinibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Mantle-Cell in search

Ovarian Neoplasms2 of 3 · compare here–

Fosun Pharma in Ovarian Neoplasms: 1 program

  1. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Ovarian Neoplasms in search

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

Pancreatic Neoplasms2 of 3 · compare here–

Fosun Pharma in Pancreatic Neoplasms: 1 program

  1. ifebemtinibno phase

Their studies: Fosun Pharma’s studies of Pancreatic Neoplasms in search

AstraZeneca in Pancreatic Neoplasms: 2 programs

  1. sonesitatug vedotinphase 3
  2. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Pancreatic Neoplasms in search

Precursor Cell Lymphoblastic Leukemia-Lymphoma2 of 3 · compare here

Johnson & Johnson in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 2 programs

  1. bleximenibphase 3
  2. fludarabinephase 2

Their studies: Johnson & Johnson’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

–

AstraZeneca in Precursor Cell Lymphoblastic Leukemia-Lymphoma: 1 program

  1. Menin Inhibitor AZD3632phase 2

Their studies: AstraZeneca’s studies of Precursor Cell Lymphoblastic Leukemia-Lymphoma in search

Uterine Cervical Neoplasms2 of 3 · compare here–

Fosun Pharma in Uterine Cervical Neoplasms: 2 programs

  1. Anti-PD-L1 Antibody-drug Conjugate HLX43phase 3
  2. bizalimogene ralaplasmidno phase

Their studies: Fosun Pharma’s studies of Uterine Cervical Neoplasms in search

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

Diabetes Mellitus, Type 12 of 3 · compare here–

Fosun Pharma in Diabetes Mellitus, Type 1: 1 program

  1. hyaluronidase (human recombinant)phase 1

Their studies: Fosun Pharma’s studies of Diabetes Mellitus, Type 1 in search

AstraZeneca in Diabetes Mellitus, Type 1: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 1 in search

Glomerulonephritis, IGA2 of 3 · compare here–

Fosun Pharma in Glomerulonephritis, IGA: 1 program

  1. XH-S003 Capsulephase 2

Their studies: Fosun Pharma’s studies of Glomerulonephritis, IGA in search

AstraZeneca in Glomerulonephritis, IGA: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Glomerulonephritis, IGA in search

Head and Neck Neoplasms2 of 3 · compare here–

Fosun Pharma in Head and Neck Neoplasms: 1 program

  1. Cetuximabphase 1

Their studies: Fosun Pharma’s studies of Head and Neck Neoplasms in search

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

Hematologic Neoplasms2 of 3 · compare here

Johnson & Johnson in Hematologic Neoplasms: 1 program

  1. teclistamabapproved, new study

Their studies: Johnson & Johnson’s studies of Hematologic Neoplasms in search

–

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

Immunoglobulin Light-chain Amyloidosis2 of 3 · compare here–

Fosun Pharma in Immunoglobulin Light-chain Amyloidosis: 1 program

  1. FKC289phase 2

Their studies: Fosun Pharma’s studies of Immunoglobulin Light-chain Amyloidosis in search

Lymphoma2 of 3 · compare here

Johnson & Johnson in Lymphoma: 1 program

  1. fludarabinephase 2

Their studies: Johnson & Johnson’s studies of Lymphoma in search

–

AstraZeneca in Lymphoma: 1 program

  1. PRMT5 Inhibitor AZD3470phase 2

Their studies: AstraZeneca’s studies of Lymphoma in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here

Johnson & Johnson in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Lymphoma, Large B-Cell, Diffuse in search

–

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Thrombosis2 of 3 · compare here

Johnson & Johnson in Thrombosis: 1 program

  1. milvexianphase 3

Their studies: Johnson & Johnson’s studies of Thrombosis in search

–

AstraZeneca in Thrombosis: 1 program

  1. andexanet alfaapproved, new study

Their studies: AstraZeneca’s studies of Thrombosis in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetJohnson & JohnsonFosun PharmaAstraZeneca
CD3Epasritamig, ramantamig, Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968, Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387, teclistamabrule, Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule, Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902ruleHLX3901, HLX3902surovatamig, Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863, Anti-GPC3 T Cell-engaging Antibody AZD9793, Anti-STEAP2/Anti-CD3/Anti-CD8 Trispecific Antibody AZD6621
EGFRAnti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446, amivantamabrule, lazertinibrulepimurutamab, HLX48, Cetuximabruleosimertinibrule
ERBB2anvatabart opadotindulpatatug, HLX87trastuzumab deruxtecanrule
BTKibrutinibrule, JNJ-64264681rule–acalabrutinibrule, pirtobrutinibrule
PDCD1–Anti-PD-1/IL-2 Fusion Protein TEV-56278, serplulimabrulerilvegostomig, volrustomig
TNFRSF17ramantamig, teclistamabrule–Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F, Allogeneic Anti-BCMA CAR T-cells AZD4045
CD274–Anti-PD-L1 Antibody-drug Conjugate HLX43, HLX37durvalumabrule
CD28Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401HLX3901, HLX3902–
FOLH1Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401, Anti-PSMA Antibody-drug Conjugate ARX517–zadavotide guraxetan
KRASolomorasib–Pan-KRAS Inhibitor JAB-23E73, AZD0240
METAnti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446, amivantamabruleHLX48–
MS4A1Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule–Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492, CT204V-CD19 × CD20rule
ARAndrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915–Androgen Receptor Degrader AZD9750rule
ATR–FXS887ruleceralasertibrule
ESR1Estrogen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0117–camizestrantrule
GPRC5Dramantamig–vemzatatug vedotin
KDR–anlotinibruleRamucirumabrule
MEN1bleximenib–Menin Inhibitor AZD3632
PRMT5onametostatrule–PRMT5 Inhibitor AZD3470
A target, or a pathogen for a vaccine, known for: Johnson & Johnson 33 of 56 · Fosun Pharma 25 of 49 · AstraZeneca 68 of 119 programs (54 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Johnson & Johnson: 4, Fosun Pharma: 18, AstraZeneca: 5).